VISCIENT BIOSCIENCES

Viscient Biosciences is a biotechnology company working at the intersection of human 3D tissue technology and multi-omics (genomics, transcriptomics, metabolomics) analysis to develop drugs across a range of therapeutic areas, with an initial focus in non-alcoholic steatohepatitis (NASH,“fatty liver disease”). Founded and staffed by a team composed of former Organovo and Ardea Biosciences scientists and entrepreneurs, Viscient is driving a revolution in drug discovery, overthrowing the old paradigm of discovery in animal models.